Shanghai Sunway Biotech Co., Ltd.

Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells. In principle, the physiological metabolic environment inside tumor cells is different from that of normal cells. Oncolytic viruses, due to their characteristics, can infect tumor cells and replicate selectively within tumor cells, leading to the dissolution and death of tumor cells. At the same time, they cannot or can only replicate in small amounts within normal cells, avoiding the impact on normal cells.  Oncolytic virotherapy is a method that uses the characteristics of oncolytic viruses as an anticancer therapy. Oncolytic virotherapy has high tumor specificity, good effects, minor side effects, and broad prospects for development. Moreover, there are precedents approved by regulatory authorities. Advantages of Oncolytic Virotherapy1. Oncolytic viruses have natural synergies with various anti-cancer drugs and therapies (including chemotherapy drugs, targeted therapies, cell therapies). They can turn "cold tumors", which are unresponsive to other immune therapies, into "hot tumors" that can respond to drugs. The combined use of both does not have obvious cumulative toxicity, thus creating a more advanced cancer treatment method. Main indications are melanoma, glioma, breast cancer, non-small cell lung cancer, colon cancer, bladder cancer, head and neck cancer, and prostate cancer. 2. The oncolytic virus can be modulated and controlled to limit its impact on normal cells, hence this therapy is expected to have minor side effects. Existing clinical data indicates that oncolytic viruses overall demonstrate better safety compared to other therapies. 3. The modification of oncolytic viruses has multiple possibilities, which can further enhance their killing power against cancer cells. For example, the virus can be modified to deliver tumor suppressor genes, or add immune regulation functions. 4. Oncolytic virotherapy is applicable to the majority of solid tumors. Due to its uniqueness, oncolytic virotherapy has drawn wide attention. However, it is still in its early stages of development. With both opportunities and challenges, it is expected that this therapy will play an important role in the treatment of solid tumors. Oncolytic virus Competitive LandscapeAccording to Patsnap Synapse, as of 24 Sep 2023, there are a total of 364 Oncolytic virus drugs worldwide, from 252 organizations, covering 136 targets, 148 indications, and conducting 493 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications,  targets, organizations, clinical trials, and clinical results related to this drug type. Approved Oncolytic virus Medicinal: Talimogene laherparepvecTalimogene laherparepvec is an oncolytic virus drug that targets CSF-2R. It has been approved for use in the treatment of various therapeutic areas including neoplasms, respiratory diseases, congenital disorders, skin and musculoskeletal diseases, and urogenital diseases. The active indications for this drug include unresectable melanoma, melanoma, triple negative breast cancer, sarcoma, breast cancer, hypospadias, malignant pleural effusion, and neoplasms. The drug was developed by Amgen, Inc., a renowned pharmaceutical company in the United States. It received its first approval in October 2015 in the United States. Talimogene laherparepvec is regulated as an orphan drug, indicating that it is intended to treat rare diseases or conditions. As an oncolytic virus, Talimogene laherparepvec works by infecting and destroying cancer cells while leaving healthy cells unharmed. It is administered through injection directly into the tumor, allowing the virus to replicate and spread within the tumor, leading to its destruction. This targeted approach offers a promising treatment option for patients with unresectable melanoma, melanoma, triple negative breast cancer, sarcoma, and breast cancer. The approval of Talimogene laherparepvec marks a significant milestone in the field of biomedicine. It provides healthcare professionals with a new tool to combat various types of cancer, particularly those that have been difficult to treat using conventional therapies. The drug's orphan drug status highlights its potential to address unmet medical needs and improve outcomes for patients with rare diseases. Since its approval, Talimogene laherparepvec has been used in clinical practice, demonstrating its safety and efficacy. Ongoing research and clinical trials are further exploring its potential applications in other therapeutic areas and indications. In conclusion, Talimogene laherparepvec is an approved oncolytic virus drug developed by Amgen, Inc. It targets CSF-2R and has shown effectiveness in treating various types of cancer, including unresectable melanoma, melanoma, triple negative breast cancer, sarcoma, and breast cancer. Its orphan drug status reflects its potential to address unmet medical needs. The drug's approval in 2015 marked a significant advancement in the field of biomedicine, offering a targeted and promising treatment option for patients with challenging-to-treat cancers. Ongoing research continues to explore its potential applications in other therapeutic areas. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Recombinant human adenovirus type 5The drug Recombinant human adenovirus type 5 is classified as an oncolytic virus, meaning it is designed to specifically target and destroy cancer cells. The drug's primary target is the p53 protein, which is involved in regulating cell growth and preventing tumor formation. By targeting p53, this drug aims to inhibit the growth and spread of cancer cells. Recombinant human adenovirus type 5 is indicated for the treatment of various diseases, including neoplasms (tumors), digestive system disorders, mouth and tooth diseases, and otorhinolaryngologic diseases. Specifically, it has shown efficacy in treating nasopharyngeal neoplasms, advanced bile duct carcinoma, and malignant ascites. The drug was developed by Shanghai Sunway Biotech Co., Ltd., an originator organization based in China. It has received approval for use globally. The first approval for this drug was granted in China in April 2006. As an oncolytic virus, Recombinant human adenovirus type 5 has shown promise in the field of biomedicine. By specifically targeting p53 and focusing on various therapeutic areas, it has the potential to provide effective treatment options for patients with different types of cancers and related diseases. The drug's approval in China indicates its safety and efficacy profile has been evaluated and deemed acceptable for use. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Overall, Recombinant human adenovirus type 5 represents a significant advancement in the pharmaceutical industry's efforts to combat cancer and related diseases. Its ability to selectively target cancer cells and its approval in multiple therapeutic areas make it a valuable addition to the treatment options available to patients. Continued research and development in this field may further enhance the drug's effectiveness and expand its applications in the future.

DUBLIN, June 20, 2022 /PRNewswire/ -- The "Gene Therapy Global Market Report 2022: By Gene, By Vector, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering. The global gene therapy market is expected to grow from $5.77 billion in 2021 to $7.37 billion in 2022 at a compound annual growth rate (CAGR) of 27.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $21.25 billion in 2026 at a CAGR of 30.3% The gene therapy market consists of sales of gene therapy related services by entities (organizations, sole traders and partnerships) that manufacture gene therapy drugs. Gene therapy is used to replace faulty genes or add new genes to cure disease or improve the body's ability to fight disease. Only goods and services traded between entities or sold to end consumers are included. The main types of gene therapy are antigen, cytokine, suicide gene and others. Antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vector, non-viral vector, others and is used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, others. it is implemented in various sectors such as hospitals, homecare, specialty clinics, others. Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. For instance, in September 2019, RMIT University, Australia has found that non-viral gene therapy can be used to speed up cancer research, which can bring patient-friendly cancer treatment in the market. The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. It is also expected to reduce turnaround time and also the cost of gene therapies. Major players in the gene therapy market are Novartis AG Bluebird Bio, inc. Spark Therapeutics, inc. Audentes Therapeutics Voyager Therapeutics Applied Genetic Technologies Corporation UniQure N.V. Celgene Corporation Cellectis S.A. Sangamo Therapeutics Gilead Lifesciences, inc. Orchard Therapeutics Sibiono GeneTech Co., Ltd. Gensight Biologics S.A. Shanghai Sunway Biotech Co., Ltd. Biogen Sarepta Therapeutics, inc. Sangamo Therapeutics Audentes Therapeutics Regenxbio, inc. Gegenxbio, inc. Oxford BioMedica plc. Dimension Therapeutics, inc. Bristol-Myers Suibb Company Sanofi Taxus Cardium Pharmaceuticals Group, inc. (Gene Biotherapeutics) Shrine plc. Benitech Biopharma Transgene Epeius Biotechnologies Corp. Calimmune, inc. Key Topics Covered: 1. Executive Summary 2. Gene Therapy Market Characteristics 3. Gene Therapy Market Trends And Strategies 4. Impact Of COVID-19 On Gene Therapy 5. Gene Therapy Market Size And Growth 5.1. Global Gene Therapy Historic Market, 2016-2021, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Gene Therapy Forecast Market, 2021-2026F, 2031F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Gene Therapy Market Segmentation 6.1. Global Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Antigen Cytokine Suicide Gene Others 6.2. Global Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Viral Vector Non-Viral Vector Others 6.3. Global Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Oncological Disorders Rare Diseases Cardiovascular Diseases Neurological Disorders Infectious Diseases Others 6.4. Global Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Hospitals Homecare Specialty Clinics 7. Gene Therapy Market Regional And Country Analysis 7.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion 7.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region, and Competitive Landscape - Analysis and Forecast, 2020-2030" - • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR• Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV• Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)• Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)Regional Segmentation• North America: U.S.• Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)• Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)Growth Drivers• Increasing Incidence of Cancer• Rising Number of Clinical Trials• Increasing Research Funding from National Cancer Institute• Increasing Adoption of Inorganic Growth Strategies in the MarketMarket Challenges• High Cost of Therapy• Lack of Therapy-Specific AssaysMarket Opportunities• Opportunities in the Emerging Economies• Drug Approvals and Strong Pipeline of Oncolytic Virus TherapiesKey Companies ProfiledAmgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: o Commercialized Therapies o Pipeline Therapies o Type of Virus o Application o RegionMarket OverviewOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body.These therapies aim at modifying genetic material for the treatment of a disease.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth.Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay.Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.Countries Covered• North America• U.S.• Europe• U.K.• Latvia• Georgia• Armenia• Germany• France• Italy• Rest-of-Europe• Asia-Pacific• China• Japan• Rest-of-APACRead the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________